全文获取类型
收费全文 | 62913篇 |
免费 | 4534篇 |
国内免费 | 264篇 |
专业分类
耳鼻咽喉 | 686篇 |
儿科学 | 1371篇 |
妇产科学 | 1057篇 |
基础医学 | 7869篇 |
口腔科学 | 869篇 |
临床医学 | 5808篇 |
内科学 | 14763篇 |
皮肤病学 | 673篇 |
神经病学 | 5882篇 |
特种医学 | 2479篇 |
外科学 | 10174篇 |
综合类 | 827篇 |
一般理论 | 72篇 |
预防医学 | 4218篇 |
眼科学 | 1891篇 |
药学 | 3879篇 |
中国医学 | 117篇 |
肿瘤学 | 5076篇 |
出版年
2023年 | 349篇 |
2022年 | 266篇 |
2021年 | 1541篇 |
2020年 | 1075篇 |
2019年 | 1555篇 |
2018年 | 1933篇 |
2017年 | 1317篇 |
2016年 | 1399篇 |
2015年 | 1685篇 |
2014年 | 2474篇 |
2013年 | 2901篇 |
2012年 | 4934篇 |
2011年 | 4949篇 |
2010年 | 2791篇 |
2009年 | 2505篇 |
2008年 | 4350篇 |
2007年 | 4557篇 |
2006年 | 4393篇 |
2005年 | 4319篇 |
2004年 | 3860篇 |
2003年 | 3551篇 |
2002年 | 3220篇 |
2001年 | 736篇 |
2000年 | 591篇 |
1999年 | 609篇 |
1998年 | 521篇 |
1997年 | 439篇 |
1996年 | 356篇 |
1995年 | 379篇 |
1994年 | 311篇 |
1993年 | 291篇 |
1992年 | 312篇 |
1991年 | 297篇 |
1990年 | 257篇 |
1989年 | 209篇 |
1988年 | 209篇 |
1987年 | 208篇 |
1986年 | 175篇 |
1985年 | 191篇 |
1984年 | 179篇 |
1983年 | 174篇 |
1982年 | 180篇 |
1981年 | 148篇 |
1980年 | 135篇 |
1979年 | 107篇 |
1978年 | 103篇 |
1977年 | 74篇 |
1976年 | 59篇 |
1974年 | 46篇 |
1973年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Matrine,oxymatrine, and compound Kushen injection from the roots of Sophora flavescens: an overview of their anticancer activities 下载免费PDF全文
In the present review, we updated current information on the chemistry, contents, and anticancer properties of matrine (MT), oxymatrine (OMT), and compound Kushen injection (CKI). The anticancer properties were focused on lung, breast, and liver cancer cells because they are most susceptible. Sources of information were from Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, Directory of Open Access Journals (DOAJ), and China National Knowledge Infrastructure (CNKI). Reference was also made on botanical websites, such as Flora of China and World Flora Online. MT and OMT are dominant quinolizidine alkaloids from the roots of Sophora flavescens (Kushen) of the family Fabaceae. Against lung, breast, and liver cancer cells, MT and OMT inhibit cell proliferation; induce cell cycle arrest, apoptosis, and autophagy; restrict angiogenesis; and inhibit cell metastasis, invasion, and migration. The processes involve various molecular targets and signaling pathways. CKI is a traditional Chinese medicine (TCM) composed of root extracts of S. flavescens and Smilax glabra (Baituling) of the family Smilacaceae. With MT and OMT as major components, CKI has been approved for the treatment of cancer in China more than 20 years ago. In recent years, systematic reviews and meta-analysis have been undertaken to evaluate the anticancer effects of CKI. When CKI is used alone and in combination with chemotherapy of western medicine, there is much to be learned concerning their interactions besides their individual and integrated efficacy. Some perspectives of MT, OMT, and CKI are discussed, and their suggestions for future research are provided. 相似文献
2.
Smita Joshi Richard Muwonge Vinay Kulkarni Mahesh Mandolkar Eric Lucas Sanjay Pujari Rengaswamy Sankaranarayanan Partha Basu 《International journal of cancer. Journal international du cancer》2023,152(2):249-258
We are reporting (a) updated incidence of cervical intraepithelial neoplasia (CIN) among women who did not have colposcopic or histopathological disease at baseline and (b) disease outcomes among women treated for CIN and their follow-up HPV status; in a cohort of women living with HIV (WHIV). The median overall follow-up was 3.5 years (IQR 2.8-4.3). The incidence of any CIN and that of CIN 2 or worse disease was 16.7 and 7.0 per 1000 person-years of observation (PYO), respectively. Compared with women who were HPV negative at baseline, women who cleared HPV infection had 23.95 times increased risk of incident CIN 2 or worse lesions (95% CI 2.40-661.07). Women with persistent HPV infection had 138.18 times increased risk of CIN 2 or worse lesions (95% CI 20.30-3300.22). Complete disease regression was observed in 65.6% of the HPV positive women with high-grade CIN and were treated with thermal ablation but HPV persistence was seen in 44.8% of those with high-grade disease. Among those who did not have any disease at baseline and were also HPV negative, about 87% (95% CI 83.79-89.48) women remained HPV negative during consecutive HPV test/s with the median interval of 3.5 years. Long-term surveillance of WHIV treated for any CIN is necessary for the prevention of cervical cancer among them. Our study provides an early indication that the currently recommended screening interval of 3 to 5 years among WHIV may be extended to at least 5 years among HPV negative women. Increasing the screening interval can be cost saving and improve scalability among WHIV to support WHO's cervical cancer elimination initiative. 相似文献
3.
4.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
5.
6.
Tran Thi Hien Ines Ambite Murphy Lam Yim Wan Michele Cavalera Parisa Esmaeili Arunima Chaudhuri Samudra Sabari Marek Babjuk Catharina Svanborg 《International journal of cancer. Journal international du cancer》2023,153(3):584-599
Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer. 相似文献
7.
Malou A.H. Nuijten Thijs M.H. Eijsvogels Valerie M. Monpellier Ignace M.C. Janssen Eric J. Hazebroek Maria T.E. Hopman 《Obesity reviews》2022,23(1):e13370
Postbariatric loss of muscle tissue could negatively affect long-term health due to its role in various bodily processes, such as metabolism and functional capacity. This meta-analysis aimed to unravel time-dependent changes in the magnitude and progress of lean body mass (LBM), fat-free mass (FFM), and skeletal muscle mass (SMM) loss following bariatric surgery. A systematic literature search was conducted in Pubmed, Embase, and Web of Science. Fifty-nine studies assessed LBM (n = 37), FFM (n = 20), or SMM (n = 3) preoperatively and ≥1 time points postsurgery. Random-effects meta-analyses were performed to determine pooled loss per outcome parameter and follow-up time point. At 12-month postsurgery, pooled LBM loss was ?8.13 kg [95%CI ?9.01; ?7.26]. FFM loss and SMM loss were ?8.23 kg [95%CI ?10.74; ?5.73] and ?3.18 kg [95%CI ?5.64; ?0.71], respectively. About 55% of 12-month LBM loss occurred within 3-month postsurgery, followed by a more gradual decrease up to 12 months. Similar patterns were seen for FFM and SMM. In conclusion, >8 kg of LBM and FFM loss was observed within 1-year postsurgery. LBM, FFM, and SMM were predominantly lost within 3-month postsurgery, highlighting that interventions to mitigate such losses should be implemented perioperatively. 相似文献
8.
Moreira Daniel C. Venkataraman Sujatha Subramanian Apurva Desisto John Balakrishnan Ilango Prince Eric Pierce Angela Griesinger Andrea Green Adam Eberhardt Charles G. Foreman Nicholas K. Vibhakar Rajeev 《Journal of neuro-oncology》2020,147(3):531-545
Journal of Neuro-Oncology - MYC-driven medulloblastomas are highly aggressive childhood tumors with dismal outcomes and a lack of new treatment paradigms. We identified that targeting replication... 相似文献
9.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
10.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721